Leerink Partnrs Predicts Atyr PHARMA Q2 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Atyr PHARMA in a note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings of ($0.17) per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Atyr PHARMA’s Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.55) EPS and FY2026 earnings at ($0.41) EPS.

Several other research firms have also commented on ATYR. Leerink Partners initiated coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a report on Friday, March 14th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Atyr PHARMA presently has a consensus rating of “Buy” and a consensus target price of $18.60.

Atyr PHARMA Stock Performance

Shares of Atyr PHARMA stock opened at $3.31 on Monday. The stock has a market capitalization of $294.60 million, a price-to-earnings ratio of -3.52 and a beta of 0.79. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The business has a 50-day moving average of $3.27 and a 200 day moving average of $3.40. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.02.

Hedge Funds Weigh In On Atyr PHARMA

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Group One Trading LLC purchased a new stake in shares of Atyr PHARMA during the fourth quarter worth approximately $26,000. XTX Topco Ltd grew its holdings in Atyr PHARMA by 74.9% during the 1st quarter. XTX Topco Ltd now owns 19,556 shares of the company’s stock worth $59,000 after acquiring an additional 8,374 shares in the last quarter. Alterna Wealth Management Inc. purchased a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $36,000. Victory Capital Management Inc. acquired a new stake in shares of Atyr PHARMA in the 4th quarter valued at $37,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Atyr PHARMA in the 4th quarter valued at $39,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.